RSV vaccine marketplace to drop 64% put up CDC determination (NYSE:PFE)
matdesign24 Healthcare analytics company Airfinity lower its U.S. marketplace forecast for respiration syncytial virus (RSV) vaccines in older adults by way of up to 64% this week after a panel of CDC
